Nevro could grab a fifth of US spinal cord stim market by 2019
This article was originally published in Clinica
Dominant players in the spinal cord stimulation market should start looking over their shoulder, as relative new kid on the block Nevro is predicted to capture around 20% of the US market four years from now.
You may also be interested in...
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.
Data from the EARLY AF First, Cryo-FIRST and STOP AF trials show cryoablation is a better option than drugs for patients with symptomatic atrial fibrillation.
In this week’s podcast, Marion Webb reviews her interview with Glooko CEO Russ Johannesson and Reed Miller explains how Boston Scientific is restructuring its transcatheter aortic valve business.